Gerd Mikus
Overview
Explore the profile of Gerd Mikus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
2263
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Saleh A, Schulz J, Schlender J, Aulin L, Konrad A, Kluwe F, et al.
Clin Pharmacokinet
. 2024 Oct;
63(11):1609-1630.
PMID: 39476315
Background And Objective: Voriconazole (VRC), a broad-spectrum antifungal drug, exhibits nonlinear pharmacokinetics (PK) due to saturable metabolic processes, autoinhibition and metabolite-mediated inhibition on their own formation. VRC PK is also...
2.
3.
Dose-dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin
Hohmann N, Friedrichs A, Burhenne J, Blank A, Mikus G, Haefeli W
Clin Transl Sci
. 2024 Aug;
17(8):e70007.
PMID: 39152679
The dose dependence of the effect of enzyme inducers and the effect of the combined administration of two inducers that exert their effect via the same induction pathway (pregnane X...
4.
Mc Laughlin A, Helland T, Klima F, Koolen S, van Schaik R, Mathijssen R, et al.
Clin Pharmacol Ther
. 2024 Mar;
116(3):690-702.
PMID: 38494911
Tamoxifen is widely used in patients with hormone receptor-positive breast cancer. The polymorphic enzyme CYP2D6 is primarily responsible for metabolic activation of tamoxifen, resulting in substantial interindividual variability of plasma...
5.
Rohr B, Krohmer E, Foerster K, Burhenne J, Schulz M, Blank A, et al.
Clin Pharmacokinet
. 2024 Feb;
63(4):469-481.
PMID: 38393578
Background: We investigated the effect of a 5-day low-dose ritonavir therapy, as it is used in the treatment of COVID-19 with nirmatrelvir/ritonavir, on the pharmacokinetics of three factor Xa inhibitors...
6.
Stoll F, Blank A, Mikus G, Czock D, Weiss J, Meyer-Tonnies M, et al.
Eur J Drug Metab Pharmacokinet
. 2023 Dec;
49(1):101-109.
PMID: 38114885
Background And Objective: Although polypharmacy is a particular challenge in daily rheumatological practice, clinical research on the effects of hydroxychloroquine (HCQ), a commonly used drug for patients with rheumatic diseases,...
7.
Krohmer E, Rohr B, Stoll F, Gumus K, Bergamino M, Mikus G, et al.
Cardiovasc Drugs Ther
. 2023 Dec;
PMID: 38112932
Purpose: Early antiviral treatment with nirmatrelvir/ritonavir is recommended for SARS-CoV-2-infected patients at high risk for severe courses. Such patients are usually chronically ill and susceptible to adverse drug interactions caused...
8.
Kluwe F, Michelet R, Huisinga W, Zeitlinger M, Mikus G, Kloft C
Clin Pharmacokinet
. 2023 Aug;
62(10):1461-1477.
PMID: 37603216
Background And Objectives: Model-informed precision dosing (MIPD) frequently uses nonlinear mixed-effects (NLME) models to predict and optimize therapy outcomes based on patient characteristics and therapeutic drug monitoring data. MIPD is...
9.
Muhareb A, Blank A, Meid A, Foerster K, Stoll F, Burhenne J, et al.
Clin Pharmacokinet
. 2023 Jul;
62(9):1305-1314.
PMID: 37505445
Background And Objective: Voriconazole is an important broad-spectrum anti-fungal drug with nonlinear pharmacokinetics. The aim of this single centre fixed-sequence open-label drug-drug interaction trial in healthy participants (N = 17)...
10.
van Leuven J, Evans S, Kichenadasse G, Steeghs N, Bonevski B, Mikus G, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444404
Precision medicine in oncology involves identifying the 'right drug', at the 'right dose', for the right person. Currently, many orally administered anti-cancer drugs, particularly kinase inhibitors (KIs), are prescribed at...